Abstract Number: 0188 • ACR Convergence 2024
Social Support in African American Women with and Without Systemic Lupus Erythematosus (SLE)
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately impacts African American women. However, this health disparity population continues to be underrepresented in research. Research suggests that social…Abstract Number: 0439 • ACR Convergence 2024
Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…Abstract Number: 0667 • ACR Convergence 2024
Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse clinical manifestations and organ involvement, posing significant challenges in its management. The emergence…Abstract Number: 2590 • ACR Convergence 2024
Pesticide Use and Incident Rheumatoid Arthritis Among Spouses in the Agricultural Health Study: An Updated Analysis
Background/Purpose: Systemic autoimmune rheumatic diseases have been associated with farming exposures, but the role of pesticides has not been well studied. The Agricultural Health Study…Abstract Number: 0260 • ACR Convergence 2024
National Survey on Patient’s Knowledge and Drivers of Human Papillomavirus (HPV) Vaccination in Immune-mediated Inflammatory Diseases (IMIDs)
Background/Purpose: Persistent human papillomavirus (HPV) infection is the cause of cervical cancer. Patients with immune-mediated inflammatory diseases (IMIDs) exposed to immunosuppressive therapy are at increased risk…Abstract Number: 0441 • ACR Convergence 2024
A Qualitative Improvement Project to Incorporate the Mycophenolate Risk Evaluation and Mitigation Strategies in an Academic Lupus Clinic
Background/Purpose: Mycophenolate Mofetil/Mycophenolic acid (MMF) is an immunosuppressant used to treat SLE. Due to the teratogenic effects of MMF, the FDA recommended universal risk evaluation…Abstract Number: 0782 • ACR Convergence 2024
30-Color Full Spectrum Flow Cytometry Identifies Sex Differences in the Circulating Immune Landscape of Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a heavily female-biased systemic autoimmune disease associated with significant morbidity and mortality due to fibrosis of the skin and vital…Abstract Number: PP16 • ACR Convergence 2024
Utilization of My Knee Notes for Enhanced Healthcare Management
Background/Purpose: Living with chronic knee issues for 40 years has been incredibly challenging. My knee pain began as early as 6th grade but got overlooked…Abstract Number: 0417 • ACR Convergence 2024
Contraception in Community Rheumatology Practices
Background/Purpose: Most prior studies of contraception in women with rheumatic disease focused on academic centers. In this study of non-academic rheumatology practices, we sought to…Abstract Number: 0445 • ACR Convergence 2024
Evaluating Clinical Reasoning in Randomized Surveys of Lupus Nephritis and Preeclampsia Pregnancy Case Workups: A Clinical Conundrum
Background/Purpose: Systemic lupus erythematosus (SLE) pregnancy is associated with a heightened risk of adverse pregnancy outcomes, including preeclampsia. Distinguishing preeclampsia from lupus nephritis (LN) presents…Abstract Number: 0809 • ACR Convergence 2024
The Utility of the sFlt1:PlGF Ratio to Rule out and Predict Preeclampsia in Women with Lupus
Background/Purpose: Women with SLE have high rates of preeclampsia caused by poor placental vascularization. The FDA recently approved the ratio of two angiogenic factors, soluble…Abstract Number: 0418 • ACR Convergence 2024
Improving Documentation of Contraception and Pregnancy Intention in Rheumatology Practice
Background/Purpose: Prior studies of RISE Registry found 9-11% of women of reproductive age with contraception documentation. We sought to identify and assess methods to increase contraception documentation…Abstract Number: 0446 • ACR Convergence 2024
Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications
Background/Purpose: Methotrexate (MTX) and mycophenolate (MMF) are two common medications for both lupus (SLE) and rheumatoid arthritis (RA). Both medications are contraindicated in pregnancy, necessitating…Abstract Number: 1065 • ACR Convergence 2024
A Quality Improvement Project to Improve Contraception Management in Patients with Systemic Lupus Erythematosus on Teratogenic Medications
Background/Purpose: Many patients with systemic lupus erythematosus (SLE) require teratogenic medications for management of their disease. Reliable contraception is important to avoid unintended pregnancy in…Abstract Number: 0420 • ACR Convergence 2024
Factors Associated with Infant Feeding Behaviors Among Women with Systemic Rheumatic Diseases
Background/Purpose: Although guidelines support acceptability of breastfeeding (BF)/pumping in women with systemic rheumatic diseases (SRDs) when taking BF-compatible medications, little is known about factors influencing…
- 1
- 2
- 3
- …
- 11
- Next Page »